A Formulation for Treating Leishmaniasis
The technology is in form of a formulation that is effective in treating intracellular protozoan parasitic infections (especially Leishmaniasis) and overcoming the associated complications. The technology provides a sterol enriched mixed lamellarity amphotericin intercalating liposomes for targeted delivery of liposomal amphotericin B thereby reducing toxicities of amphotericin B. The liposomal formulation is sonicated before administration to increase the plasma half-life of the liposomal drug for facilitating better bio-distribution in the body. The formulation is sugar free and thus can be freely use by diabetics. The technology has been tested on the mice for tolerance study. Lipid-Based Amphotericin B vs Amphotericin B Lipid-based formulation produces results comparable to those of amphotericin B, with less toxicity. The lipid-based form of amphotericin B is given at a higher dosage than amphotericin B. Lipid-based amphotericin B is indicated for management of invasive fungal infection in patients who are refractory to or intolerant of amphotericin B.
Sector: Pharmaceuticals
Country: India
Area of Application: Pharma industry.
Keywords: Leishmaniasis, Amphotericin-B, efficacies.
Advantages: Amphotericin-B is the drug of choice in India. Drug is less toxic. Huge market in India Can be use freely by diabetic patients. Can be useful against fungal infections. More potent, efficacious and effective.
Environmental aspects: Not Applicable
Development Status: Laboratory Model
Legal Protection: Patent in Progress
Technical specifications:  
Transfer Terms: Technology Licensing
Target Countries: India
Estimated cost (US$):  
Upload any relevant document:  
Contact Person: SkyQuest Technology Consulting Pvt. Ltd.
Address: 501, Krishna Complex, Opp. Devashish School, Bodakdev
City: Ahmedabad
Country: India
Zip/Pin Code: 380054

Contact Technology Provider